Evaluation of epidermal growth factor receptor tyrosine kinase inhibitor to treat patients with advanced non-small cell lung cancer
WANG Guanghui
XU Yang
LIU Yongmou
ZHANG Jinping
Abstract：Objective To investigate the efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibi -tor (EGFRT-TKI) in treatment of advanced non-small cell lung cancer (NSCLC).Methods Patients with advanced NSCLCof 160 cases underwent EGFR-TKI gefitinib or erlotinib treatmen,t of which 77 cases (48.1%) as first-line treatment group,83 cases (51.9 %) as second-line treatment group.The clinical features, treatment outcome and survival time were observed ,and evaluated the drug safety.Results The total effective rate of EGFR-TKI was 33.8% (54/160), disease control rate was74.4% (119/160).The median survival time of no progress was 9.8 months, the median survival time was 14.5 months, 1year survival rate was 55%.Multivariate Logistic regression analysis showed,pathological type,skin rash and changes of serumCEA associated with the effective rate ( P <0.05); pathological type, smoking history, skin rash, changes of serum CEAwere correlated with disease control rate ( P <0.05); pathological types were independent factors affecting the progressionfree surviva,l PS was an independent prognostic factors for survival .The first-line and second-line treatment efficacy were similar.Adverse drug reactions including rash and mild diarrhea .Concluis on It demonstrated that the EGFR-TKI is safety andeffective in treatment of advanced NSCLC .
Keywords：Non-small cea lung canceradvancedEpidermal growth factor receptor tyrosine kinase inhibitorsTreatment
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 686-689,693 )